Similarly, in the P024 study, in which Letrozole and TMX were compared in neoadjuvant therapy in patients with ER+/PR+ breast cancer, patients with ER≥10% positive were included and a linear correlation was reported between ER expression levels and response (46). This evidence concerns the gene ESR1 and breast carcinoma.